ASLAN Pharmaceuticals Long Term Debt

ASLAN Pharmaceuticals (ASLN) currently reports a long-term debt of $19M as of March 2024. That compares with $27M in the prior-year period — down 28.8% year over year. Use the charts on this page to explore ASLAN Pharmaceuticals's long-term debt history and peer comparisons.

ASLAN Pharmaceuticals's long-term debt decreased from $27M to $19M — a 28.8% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ASLAN Pharmaceuticals reported $19M in long-term debt as of March 2024. That compares with $27M in the prior-year period — down 28.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ASLAN Pharmaceuticals, and consider following ASLN for alerts when major investors trade the stock.

ASLAN Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASLN with unrelated industries.